Albemarle heads into its May 6 Q1 earnings call with short sellers adding aggressively and options traders more defensive than they've been in months — a setup that contrasts sharply with a Street that just upgraded its view of the stock.
Short interest has climbed materially this week. From 7.1% of free float in early March, SI has risen to 9.2% — a jump of more than 10% on the week alone and nearly 15% over the past month. That pace of rebuilding is the standout feature of the current positioning picture. Borrow costs are rising too, up 34% over the past week to 0.37% — still inexpensive in absolute terms, but the direction is clearly tightening. Availability in the lending pool remains ample, which means new short positions face little friction: there is no squeeze dynamic in the borrow market, and fresh bears can establish positions without difficulty.
Options traders have turned more defensive in the same breath. The put/call ratio has hit 1.20 — more than two standard deviations above its 20-day average of 1.11. That is its most elevated reading in at least several weeks, though still well below the 52-week peak of 1.80. The signals from short interest and options are pointing in the same direction: hedging demand has accelerated into the print. The ORTEX short score has also crept higher this week, moving from 46.3 to 49.2 over the past eight sessions — not alarming on its own, but consistent with the overall trend toward more cautious positioning.
The Street has been moving the other way. Most of the major analyst actions in the past two weeks have been bullish on price. BofA raised its target from $190 to $225 this week while reiterating Buy. RBC lifted to $245 from $216 on April 24, also maintaining Outperform. Truist similarly raised to $245. Citigroup nudged its Neutral target to $210 from $190. The lone dissent was Baird, which downgraded to Neutral on April 17 while holding its $210 target. The consensus mean target is $197.47, a modest premium to the current price of $186.90. The bulls point to Albemarle's integrated lithium position and cost discipline as levers for free cash flow recovery; the bear case centres on lithium price volatility, weak EV demand visibility, and the risk that capex restraint delays any real market recovery. EV/EBITDA has compressed to roughly 10.9x over the past 30 days — down nearly 1.7 turns — reflecting how quickly the narrative has shifted on commodity price expectations. Two factor scores stand out: EPS surprise ranks in the 97th percentile and EPS momentum over 90 days is similarly elite, suggesting the company has been consistently beating estimates even as the macro backdrop stays difficult.
The earnings history adds colour. The last print in February saw the stock fall around 5.7% the next day, though it partially recovered over the following week. The prior release produced a similar 5% one-day drop. A pattern of post-earnings softness is clearly visible.
Closest US-listed peer SQM fell 2% on Tuesday but is up 2.5% on the week, a notably calmer ride than ALB's 6.3% one-day drop and 5.8% weekly decline. ECVT barely moved on the week. The divergence suggests some of the pressure on ALB is name-specific rather than sector-wide — which makes the May 6 print, and management's commentary on lithium price expectations, the natural focal point for what happens next.
See the live data behind this article on ORTEX.
Open ALB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
